Search Results - Amy Axel

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

    Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells by Nicholas J. Sullivan, A. Kate Sasser, Amy Axel, Farhad Vesuna, Venu Raman, Nilsa C. Ramirez, Tatiana M. Oberyszyn, Brett M. Hall

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

    Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) by Niels W.C.J. van de Donk, Henny G. Otten, Omar El Haddad, Amy Axel, A. Kate Sasser, Sandra Croockewit, Joannes F.M. Jacobs

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening

    Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening by Eberhard Krausz, Ronald De Hoogt, Emmanuel Gustin, Frans W. Cornelissen, Thierry Grand‐Perret, Lut Janssen, Nele Vloemans, Dirk Wuyts, Sandy Frans, Amy Axel, Pieter J. Peeters, Brett M. Hall, Miroslav Cik

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference by Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi, A. Kate Sasser

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

    Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus by Suzanne Cole, Alice M. Walsh, Xuefeng Yin, Mihir D. Wechalekar, Malcolm Smith, Susanna Proudman, Douglas J. Veale, Ursula Fearon, Costantino Pitzalis, Frances Humby, Stefano Bombardieri, Amy Axel, Homer Adams, Christopher Chiu, Michael Sharp, John Alvarez, I.E. Anderson, Loui Madakamutil, Sunil Nagpal, Yanxia Guo

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

    CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma by Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy Axel, Khaja Syed, Richard W.J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W.C.J. van de Donk

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

    Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab by Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Berris van Kessel, Martijn W. Heymans, Lisa C. Holthof, Christie P.M. Verkleij, Rengasamy Boominathan, Bhavesh Vaidya, Jocelyn Sendecki, Amy Axel, François Gaudet, Kodandaram Pillarisetti, Sonja Zweegman, Homer Adams, Tuna Mutis, Niels W.C.J. van de Donk

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

    Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma by Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin, Kristine A. Frerichs, Rowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth J. Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy P. Wong, Raluca Verona, Pieter Sonneveld, Sonja Zweegman, Homer Adams, Tuna Mutis, Niels W.C.J. van de Donk

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

    Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab by Tineke Casneuf, Homer Adams, Niels W.C.J. van de Donk, Yann Abraham, Jaime Bald, Greet Vanhoof, Koen Van der Borght, Tina Smets, Brad Foulk, Karl C. Nielsen, Joshua Rusbuldt, Amy Axel, Andrew C. Lysaght, Hugo Ceulemans, Frederik Stevenaert, Saad Z. Usmani, Torben Plesner, Hervé Avet‐Loiseau, Inger S. Nijhof, Tuna Mutis, Jordan M. Schecter, Christopher Chiu, Nizar J. Bahlis

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: